4,870 Shares in Novo Nordisk A/S (NYSE:NVO) Purchased by May Hill Capital LLC

May Hill Capital LLC acquired a new position in Novo Nordisk A/S (NYSE:NVO - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 4,870 shares of the company's stock, valued at approximately $419,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Headlands Technologies LLC bought a new position in Novo Nordisk A/S during the 4th quarter valued at $893,000. Boston Family Office LLC boosted its stake in Novo Nordisk A/S by 0.6% during the fourth quarter. Boston Family Office LLC now owns 44,804 shares of the company's stock valued at $3,854,000 after buying an additional 280 shares in the last quarter. OLD Mission Capital LLC bought a new position in Novo Nordisk A/S during the fourth quarter valued at about $43,275,000. Mosaic Financial Group LLC raised its position in Novo Nordisk A/S by 180.7% in the fourth quarter. Mosaic Financial Group LLC now owns 4,856 shares of the company's stock worth $418,000 after acquiring an additional 3,126 shares in the last quarter. Finally, HighPoint Advisor Group LLC lifted its holdings in Novo Nordisk A/S by 4.5% in the 4th quarter. HighPoint Advisor Group LLC now owns 19,348 shares of the company's stock valued at $1,620,000 after acquiring an additional 841 shares during the last quarter. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Up 0.2 %

Shares of NYSE NVO traded up $0.17 during mid-day trading on Wednesday, reaching $68.20. The company had a trading volume of 7,301,268 shares, compared to its average volume of 5,588,217. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The company has a market capitalization of $306.05 billion, a price-to-earnings ratio of 20.73, a PEG ratio of 0.90 and a beta of 0.42. The stock has a fifty day moving average of $81.89 and a two-hundred day moving average of $97.68. Novo Nordisk A/S has a 12-month low of $66.57 and a 12-month high of $148.15.

Remove Ads

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be issued a $0.7874 dividend. This represents a yield of 1.2%. The ex-dividend date is Monday, March 31st. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. Novo Nordisk A/S's dividend payout ratio (DPR) is 47.72%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Sanford C. Bernstein upgraded Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. StockNews.com lowered Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research note on Friday, March 21st. Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Finally, Stifel Nicolaus cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.